Cargando…
Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455245/ https://www.ncbi.nlm.nih.gov/pubmed/32843335 http://dx.doi.org/10.1136/jitc-2020-000878corr1Amendment |
| _version_ | 1783575592756576256 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7455245 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74552452020-08-31 Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19' J Immunother Cancer Correction BMJ Publishing Group 2020-08-25 /pmc/articles/PMC7455245/ /pubmed/32843335 http://dx.doi.org/10.1136/jitc-2020-000878corr1Amendment Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Correction Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19' |
| title | Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
|
| title_full | Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
|
| title_fullStr | Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
|
| title_full_unstemmed | Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
|
| title_short | Amendment to 'Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19'
|
| title_sort | amendment to 'correction: insights from immuno-oncology: the society for immunotherapy of cancer statement on access to il-6-targeting therapies for covid-19' |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455245/ https://www.ncbi.nlm.nih.gov/pubmed/32843335 http://dx.doi.org/10.1136/jitc-2020-000878corr1Amendment |